Scancell Holdings Plc · LSE:SCLP

Scancell — H1 FY2026 Earnings Presentation

18 slides from Scancell's earnings presentation, Jan 29, 2026

  1. Slide 1: Transforming Cancer Care: FY 2026 Interim Results

    Transforming Cancer Care Active Immunotherapy for a Cancer Free Future FY 2026 Interim Results 29th January 2026

  2. Slide 2: Disclaimer

    DISCLAIMER For the purposes of this disclaimer, this “presentation” shall mean and include the slides that follow, the oral presentation of the slides by Scancell Holdings plc (the “Company”) or any person on its behalf, any question-and- answer session that follows the oral presentation, hard copie

  3. Slide 3: Interim Financials Key Highlights

    INTERIM FINANCIALS KEY HIGHLIGHTS R E G I ST R AT I O N A L P 3 ST U DY TO R E D E F I N E S o C I N A DVA N C E D M E L A N O M A  iSCIB1+, a novel DNA active immunotherapy, has shown best in class potential to redefine standard of care for first line unresectable melanoma. This is a significant u

  4. Slide 4: Scancell Pipeline

    SCANCELL PIPELINE L E A D A S S E T R E A DY F O R R E G I ST R AT I O N A L ST U DY Product Indication Therapy Type Preclinical Phase I Phase II Phase III Milestones Adjuvant SCIB1 Monotherapy Complete Melanoma SCIB1/ iSCIB1+ Advanced Combination PHASE 32 Phase 3 start mid-2026 Scancell Clinical (S

  5. Slide 5: iSCIB1+ Redefining Standard of Care in Advanced Melanoma

    iSCIB1+ Redefining Standard of Care in Advanced Melanoma 5

  6. Slide 6: iSCIB1+ Has the Potential to Create a New Standard of Care for Melanoma

    ISCIB1+ HAS THE POTENTIAL TO CREATE A NEW STANDARD OF CARE FOR MELANOMA ~325,000 global melanoma incidence 1 Approved Therapies Unmet Need Resectable Melanoma Stage IB - IIIA Pembrolizumab (Keytruda) ~58,000 deaths per year Neoadjuvant Checkpoint Inhibitor Monotherapy * Ipilimumab (Yervoy) plus Nivo

  7. Slide 7: Commercial Building Blocks in Place

    COMMERCIAL BUILDING BLOCKS IN PLACE A DVA N C I N G P L A N N I N G F O R P H A S E 3 D E V E LO P M E N T PRODUCT IP MANUFACTURING DELIVERY REGULATORY COMMERCIAL Meaningful Off the shelf Regulatory support Partnering for Clinical benefit Needle-free Strong global IP US FDA Clearence seamless Conven

  8. Slide 8: iSCIB1+ Is a DNA ImmunoBody with a Novel Mechanism of Action

    iSCIB1+ IS A DNA IMMUNOBODY® WITH A NOVEL MECHANISM OF ACTION First Generation Second Generation Target Delivered Needle-Free into patients binding FC region HLA A2 Restricted Broader HLA Population AvidiMab® FC modification  DNA ImmunoBody is a plasmid encoding a modified antibody;  Target Bindin

  9. Slide 9: iSCIB1+ Is a Differentiated Immunotherapy for Melanoma

    iSCIB1+ IS A DIFFERENTIATED IMMUNOTHERAPY FOR MELANOMA Targeting known Melanoma specific targets: GP100 & TRP-2  overcoming weak or wrong antigens Compelling Target activated dendritic cells in-vivo Science  overcoming inadequate immune system priming Non-personalised approach  scalable and cost-

  10. Slide 10: iSCIB1+: PFS in Target HLA Population Against Historic Controls

    iSCIB1+: PFS in target HLA population against historic controls S T R O N G D E LTA O V E R I P I L I M U M A B A N D N I V O L U M A B F R O M C H E C K M AT E 0 6 7 1.0  iSCIB1+ showing 24% delta 0.9 over median PFS for SoC (ipi/nivo, Checkmate 067) 0.8 PFS at 16iSCIB1+ months(PFS = 74% at 16 mon

  11. Slide 11: Phase 3 Double Blinded Randomised Adaptive Registrational Study

    PHASE 3 DOUBLE BLINDED RANDOMISED ADAPTIVE REGISTRATIONAL STUDY I N D I CAT I V E P L A N Selected Product: Post Registration iSCIB1+ Registration (in-market) Analysis Analysis Target Population: • Stage III & IV unresectable melanoma iSCIB1+ ipi +nivo • HLA Haplotypes: A2, A3, 1:1 A31, B35, B44, Bw

  12. Slide 12: Risk Mitigation on Study Design

    RISK MITIGATION ON STUDY DESIGN  Phase 2 was a translation study to determine parameters for Phase 3  Statistical power modelled on conservative delta from Phase 2  Adaptive design included to enable size increase  Detailed assessment of patient characteristics vs historic SoC studies (Checkmate

  13. Slide 13: Regulatory Strategy with Positive Momentum

    REGULATORY STRATEGY WITH POSITIVE MOMENTUM FDA – IND cleared 23 Jan 2026 MHRA & EMA • Type B/Pre-IND meeting held • Scientific reviews also completed • Accepted our proposed 8mg intramuscular dose (Project Optimus ✓) • Good alignment with FDA perspectives • Data, study design and stats plan, endpoin

  14. Slide 14: Validated ImmunoBody Platform Expansion to Additional Cancers

    VALIDATED IMMUNOBODY PLATFORM EXPANSION TO ADDITIONAL CANCERS T- C E L L R E P R O G R A M M I N G P L AT F O R M Forces MHC Breaks tolerance Builds durable Does the above Dual mechanism class I cross to weak/self high avidity CD8 in an antigen- of action presentation antigens memory restricted way

  15. Slide 15: Multiple Major Markets Today & Major Potential Expansion

    MULTIPLE MAJOR MARKETS TODAY & MAJOR POTENTIAL EXPANSION Platform Tumour Current Future 1L Metastatic Neoadjuvant/Adjuvant iSCIB1+ Melanoma (registrational) ✓ Uveal, Acral, Mucosal Brain cancer Glioblastoma iSCIBx Solid tumours PDAC, Ovarian, CRC, others (ImmunoBody®) Modi-1 HNSCC Phase 2 ✓ Phase 2b

  16. Slide 16: Financial Highlights

    FINANCIAL HIGHLIGHTS C A S H R U N W AY T O H 2 2 0 2 6 W I T H A D D I T I O N A L U P S I D E O P P O R T U N I T I E S Consolidated Statement of 6 months 6 months Comprehensive Loss (£m) 31 October 2025 31 October 2024 Revenue - -  Additional Genmab milestones anticipated in 2026. Most recent Gr

  17. Slide 17: Scancell Development Milestones

    SCANCELL DEVELOPMENT MILESTONES M U LT I P L E N E A R - T E R M M I L E S T O N E S Product H1 2026 H2 2026 US FDA IND Clearance ✓ Build US clinical capabilities Scancell Clinical iSCIB1+ US Fast Track Application P3 Registrational Study Initiation1 UK, EMA and other Regulatory clearances PFS data

  18. Slide 18: <x Se C’

    <x Se C’

Scancell Holdings — H1 FY2026 Earnings Presentation on 6ix